OcuNexus Board of Directors

James Mervis -- CHAirman - Former Chairman and Director Intercept Pharmaceuticals, Inc. Co-founder Cardiokine, Inc.

Mr. Mervis has been a catalyst for success in technology-based companies in life sciences and communications. He has an extensive background in securities and commercial transactions, defining and establishing strategic alliances, and securing the financial and human resources for corporate growth. Mr. Mervis was formerly Chairman of the Board of Directors at Intercept Pharmaceuticals, Inc. and Co-Founder/Senior Vice President, Corporate Development at Cardiokine, Inc. He was also a co-founder of Barrier Therapeutics, Inc. (BTRX), the successful spin-out of Johnson & Johnson's (JNJ) dermatology development portfolio. Before Barrier, Mr. Mervis was Entrepreneur-in-Residence at Apple Tree Partners, L.L.C. and Co-Founder & Executive Vice President of MedicinePlanet Inc., a developer of healthcare services for the mobile world. He was also a Founder & Managing Director of Crunch Media Corporation, a multimedia production company where he was producer/co-creator of A Brief History of Time with Stephen Hawking: An Interactive Adventure. Mr. Mervis received his J.D. from Fordham University School of Law and his B.S. from Cornell University.

James Blair -- Managing Partner, Domain Associates

Mr. Blair has been a Partner of Domain since its founding in 1985. Present board memberships include Cadence Pharmaceuticals, Cell Biosciences, Five Prime Therapeutics, GenVault, NeuroPace, Novacea, NuVasive, Pharmion and Volcano. Mr. Blair has over thirty-five years experience with venture and emerging growth companies. In the course of this experience, he has been involved in the creation and successful development at the Board level of over forty life sciences ventures, including Amgen, Aurora Biosciences, Amylin Pharmaceuticals, Applied Biosystems, Dura Pharmaceuticals, GeneOhm Sciences and Molecular Dynamics. A former managing director of Rothschild Inc., Mr. Blair was directly involved at a senior level with Rothschild/New Court venture capital activities from 1978 to 1985. From 1969 to 1978, he was associated with F.S. Smithers and Co. and White, Weld and Co., two investment banking firms actively involved with new ventures and emerging growth companies. From 1961 to 1969, Mr. Blair was an engineering manager with RCA Corporation, during which time he received a David Sarnoff Fellowship. He currently serves on the Board of Directors of the Prostate Cancer Foundation, and he is on the Advisory Boards of the Department of Molecular Biology at Princeton University and the Department of Biomedical Engineering at the University of Pennsylvania. Mr. Blair graduated from U. of Pennsylvania with his M.S.E. and Ph.D. in 1969 and from Princeton University with his B.S.E. in 1961.

Dr. Brian Levy O.D., M.Sc. -- Chief Executive Officer - Refer Management Page

Howard E. (“Ted”) Greene -- Founding CEO, Amylin Pharmaceuticals, Inc.

Howard E. Greene Co-Founder and former Director - Mr. Greene is a co-founder of Amylin Pharmaceuticals and formerly served as a Director at Amylin since its inception in 1987. Mr. Greene serves on the Audit Committee and the Finance Committee. Mr. Greene is an entrepreneur who has participated in the founding and/or management of eleven medical technology companies over two decades, including three companies for which he served as chief executive officer. From 1987 to 1996, Mr. Greene served as Amylin’s Chief Executive Officer. From 1986 until 1993, Mr. Greene was a founding general partner of Biovest Partners, a seed venture capital firm. He was Chief Executive Officer of Hybritech from 1979 until its acquisition by Eli Lilly and Company in 1986, and he was co-inventor of Hybritech’s patented monoclonal antibody assay technology. Prior to joining Hybritech, he was an executive with the medical diagnostics division of Baxter Healthcare Corporation from 1974 to 1979 and a consultant with McKinsey & Company from 1967 to 1974. Mr. Greene received an M.B.A. from Harvard University.

Inna Martin Eitan -- RMI PARTNERS

Inna Martin Eitan has over 16 years of business development, managerial and entrepreneurial experience in the pharmaceutical and medical device industries. Prior to joining RMI Partners, she founded and managed a consultancy firm that provided business development and consulting services to companies in the pharma, medtech and biotech fields.  Inna has also served as a strategic business development and financial consultant to several leading venture funds and companies traded at NASDAQ in USA and Canada and TASE in Israel. She provided consulting on business development and investment raising issues for such biomedical technology companies as Hadassit Bio Holdings, BetaO2, Godji, Maayan Ventures, Peregrine, Molecular Cytomics, Nextar (Aminolab Pharma)and world-known division of Stem Cell Research at the Technion Research & Development Foundation in Israel.  In addition to participating in the development of RMI Partners, Inna also is a member of the Board of Directors of ReVision Optics Inc. аnd Ocon Medical Ltd.